PMC7586266_01
Maculopapular rash of neck.
10.1177_2050313X20966895-fig1.jpg
PMC7586266_01_10.1177_2050313X20966895-fig1.jpg
fig1-2050313X20966895
On examination, she was afebrile, with vital signs within normal limits; maculopapular rash seen on neck (Figure 1), back (Figure 2) and face with BSA >= 30%, (Grade 3) with a Naranjo score of 9 (previous conclusive report on this reaction +1, adverse event appear after drug administered +2, adverse event improved when drug discontinued +1, causal association known and re-challenge at the same dose cannot be done +2, alternative causes +2, confirmed by objective clinical evidence +1).
Maculopapular rash of back.
10.1177_2050313X20966895-fig2.jpg
PMC7586266_01_10.1177_2050313X20966895-fig2.jpg
fig2-2050313X20966895
On examination, she was afebrile, with vital signs within normal limits; maculopapular rash seen on neck (Figure 1), back (Figure 2) and face with BSA >= 30%, (Grade 3) with a Naranjo score of 9 (previous conclusive report on this reaction +1, adverse event appear after drug administered +2, adverse event improved when drug discontinued +1, causal association known and re-challenge at the same dose cannot be done +2, alternative causes +2, confirmed by objective clinical evidence +1).
Case timeline and desensitization protocol.
10.1177_2050313X20966895-fig3.jpg
PMC7586266_01_10.1177_2050313X20966895-fig3.jpg
fig3-2050313X20966895